Compare Merck & Co., Inc. (MRK) vs SanDisk (SNDK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs SanDisk — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while SanDisk trades at $1,581.82 (market cap $232.61B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Merck & Co., Inc. pays a 2.39% dividend while SanDisk pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and SanDisk for 8 Days on average.
| MRK | SNDK | |
|---|---|---|
Market Cap | $351.28B | $232.61B |
Volume | 7,969,665 | 9,218,054 |
Sector | Health | Technology |
52-Week High | $156.43 | $2.34K |
52-Week Low | $82.49 | $116.91 |
Typical Hold Time | 98 Days | 8 Days |
Enterprise Value | $398.04B | $228.03B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
SNDK trades at $1,581.82, down 6.54% amid recent volatility, yet maintains strong analyst support with 87.5% buy ratings and a $2,160 consensus price target. The stock shows exceptional profitability metrics including 71.47% gross margins and 91.64% ROE, though current earnings reflect a net loss of -$1.64B for 2025. Recent news highlights institutional positioning shifts and AI-driven memory demand dynamics affecting performance.
Outlook remains cautiously optimistic given projected 2026 revenue growth to $20.2B and net profit of $11.4B, but risks include memory cycle volatility and competitive pressures. Technical indicators suggest near-term bearish pressure with key support at $1,575, while fundamental strength in profitability metrics supports long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About SanDisk
Sandisk is a semiconductor memory company specializing in NAND flash technology. Its storage products support consumer devices, enterprise systems, and cloud and AI infrastructure.
Read more on SNDK →
